Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIPHENYLAN SODIUM vs ELEPSIA XR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phenytoin, the active component, stabilizes neuronal membranes by promoting sodium efflux and inhibiting sodium influx, thereby limiting the spread of seizure activity. It also reduces voltage-gated sodium channel activity.
Levetiracetam, the active component, binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. The exact mechanism of antiepileptic effect is unknown.
FDA-approved: Generalized tonic-clonic seizures, complex partial seizures,Off-label: Prevention of seizures during neurosurgery, status epilepticus (parenteral), trigeminal neuralgia
Adjunctive therapy for partial-onset seizures in adults and pediatric patients aged 4 years and older with epilepsy,Off-label: status epilepticus, migraine prophylaxis (limited evidence)
100 mg orally every 8 hours
ELEPSIA XR (levetiracetam extended-release) 1000 mg orally once daily. May be increased by 1000 mg/day every 2 weeks to a maximum of 3000 mg once daily.
22 hours (range 10-34 hours); prolonged in hepatic impairment or with CYP inhibitors; correlates with time to steady state (~5 days).
Terminal elimination half-life is 14-17 hours; requires dose adjustment in renal impairment.
Primarily hepatic metabolism via CYP2C9 and CYP2C19 isoenzymes, with saturation kinetics at therapeutic concentrations. Major metabolite: 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH).
Partially hydrolyzed by esterases in plasma and tissues; minor metabolism via CYP450 enzymes (CYP3A4, CYP2C9, CYP2C19) to inactive metabolites. Approximately 66% excreted unchanged in urine.
Primarily hepatic metabolism via CYP450; <5% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 20-30% of metabolites.
Primarily renal (70% unchanged, 20% as inactive metabolites); minor fecal (10%).
90-95% mainly to albumin; displaces and is displaced by other highly protein-bound drugs.
92-97% bound to serum albumin.
0.6-0.8 L/kg; larger in neonates (up to 1.2 L/kg); indicates extensive tissue binding, particularly in brain and adipose.
0.9-1.1 L/kg; indicates moderate extravascular distribution.
Oral: 85-95% (capsules and tablets); intramuscular: 70-80% due to precipitation at injection site.
Oral: Approximately 80% with food; may be lower on empty stomach.
No adjustment required for GFR >30 m L/min; for GFR 10-30 m L/min, administer every 12-24 hours; for GFR <10 m L/min, administer every 24 hours with monitoring of serum levels
For creatinine clearance (Cr Cl) 50-80 m L/min: 1000 mg every 24 hours. Cr Cl 30-49 m L/min: 500 mg every 24 hours. Cr Cl <30 m L/min: 250 mg every 24 hours. End-stage renal disease on dialysis: 500 mg every 24 hours with a supplemental dose of 500 mg after dialysis.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25-50%; Child-Pugh Class C: avoid use or reduce dose by 50-75% with close monitoring
Mild to moderate hepatic impairment (Child-Pugh A or B): No dose adjustment required. Severe hepatic impairment (Child-Pugh C): Reduce dose by 50%; for Cr Cl <60 m L/min, adjust both for renal function and hepatic impairment.
5-7 mg/kg/day orally divided every 8-12 hours, not to exceed 300 mg/day
ELEPSIA XR is not indicated for pediatric patients. Immediate-release levetiracetam dosing for pediatric epilepsy: 20 mg/kg/day in two divided doses, titrated up to 40-60 mg/kg/day based on response; maximum 3000 mg/day for children ≥12 years.
Initial dose of 50 mg orally every 8 hours, titrate slowly based on response and tolerability; monitor renal function and serum levels
Elderly patients (>65 years) often have reduced creatinine clearance. Adjust dose based on renal function (see renal_adjustment). Start at lower end of dosing range; monitor for somnolence and dizziness.
Intravenous administration: Risk of serious cardiovascular reactions including hypotension and cardiac arrest, especially in elderly patients and those with underlying cardiac disease. Rate of infusion should not exceed 50 mg/min in adults.
Not applicable (no FDA boxed warning).
1. Cardiovascular risk with IV administration. 2. Suicide risk and behavioral changes. 3. Hepatotoxicity (monitor LFTs). 4. Hematologic effects (agranulocytosis, thrombocytopenia). 5. Lymphadenopathy. 6. Teratogenicity (fetal hydantoin syndrome). 7. Hyperglycemia. 8. Withdrawal seizures. 9. Dermatologic reactions (Stevens-Johnson syndrome). 10. Osteoporosis with chronic use.
Psychiatric adverse reactions: including agitation, hostility, aggression, anxiety, and paranoid reactions, which may be severe. Monitor for behavioral changes.,Suicidal ideation and behavior: increased risk of suicidal thoughts or behavior in patients taking antiepileptic drugs. Monitor for emergence or worsening of depression.,Somnolence and dizziness: common, impairing ability to drive or operate machinery.,Withdrawal seizures: abrupt discontinuation may increase seizure frequency. Taper gradually.
Absolute: Hypersensitivity to phenytoin, hydantoins, or any component; sinus bradycardia, sinoatrial block, second- or third-degree AV block, or Stokes-Adams syndrome (IV formulation); concurrent use with delavirdine. Relative: Pregnancy (especially first trimester; weigh risk vs benefit), hepatic impairment, alcoholism, porphyria.
Hypersensitivity to levetiracetam or any component of the formulation
Avoid grapefruit and grapefruit juice as it inhibits CYP metabolism and can increase phenytoin levels. Enteral feeding formulas may reduce absorption; administer phenytoin 1-2 hours before or after enteral feeds. High doses of folic acid may decrease phenytoin levels. Chronic use can lead to vitamin D and folate deficiency; consider supplementation if indicated. Alcohol consumption should be minimized—acute intake can increase levels while chronic use decreases them.
Avoid high-fat meals as they may delay absorption. No specific food restrictions, but maintain adequate hydration to prevent nephrolithiasis.
First trimester: Increased risk of major congenital malformations including neural tube defects, cleft palate, and congenital heart defects. Second and third trimesters: Risks of bleeding disorders in the newborn due to vitamin K deficiency, and potential for neonatal withdrawal and growth restriction.
First trimester: Increased risk of major congenital malformations including neural tube defects, cleft palate, and cardiac defects due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction, preterm birth, and neonatal hemorrhage. Third trimester: Potential for kernicterus and transient neonatal hemolytic anemia. Antiepileptic Drug (AED) use in pregnancy overall associated with developmental delay and autism spectrum disorder.
Diphenhydramine is excreted into breast milk in small amounts; reported M/P ratio is approximately 0.5 to 1.0. In infants, risks of drowsiness, irritability, and paradoxical excitation. Generally considered compatible with breastfeeding, but monitor infant for adverse effects.
Excreted into breast milk; M/P ratio approximately 0.2-0.4. American Academy of Pediatrics recommends caution due to potential for hepatotoxicity and hemolytic anemia in the neonate. Avoid breastfeeding if alternative agents available.
No specific dose adjustments are typically required. However, due to increased volume of distribution and metabolism in pregnancy, therapeutic levels may need monitoring. Initial dose adjustments are not recommended, but consider dose increases if clinical response is inadequate.
Serum levels decline by 50-70% in pregnancy due to increased volume of distribution and hepatic metabolism; total daily dose may need to be increased by 30-50% in second and third trimesters. Monitor free drug concentrations and adjust to maintain therapeutic range. Reduce dose postpartum to pre-pregnancy levels gradually over 1-2 weeks.
Diphenylan Sodium (phenytoin sodium) is a hydantoin anticonvulsant used for generalized tonic-clonic and complex partial seizures. It exhibits zero-order kinetics at therapeutic levels; small dose increases can cause disproportionate toxicity. Monitor for nystagmus, ataxia, and mental status changes as early signs of toxicity. Due to high protein binding (90%), hypoalbuminemia or uremia increases free fraction—adjust doses based on free phenytoin levels. Can cause folate deficiency, megaloblastic anemia, and bone density loss. Gingival hyperplasia occurs in 40% of patients; meticulous oral hygiene can reduce severity. Dosing must be individualized with therapeutic range 10-20 mg/L total (1-2 mg/L free). Intravenous loading requires cardiac monitoring due to risk of bradycardia and hypotension; avoid IM use due to crystallization and erratic absorption.
ELEPSIA XR (topiramate extended-release) is indicated for epilepsy and migraine prophylaxis. Titrate slowly to minimize cognitive side effects. Monitor for metabolic acidosis, especially in patients with predisposing conditions. Contraindicated in pregnancy due to risk of oral clefts. Adjust dose in renal impairment (Cr Cl <70 m L/min).
Take exactly as prescribed; do not stop abruptly as withdrawal can trigger seizures.,Avoid alcohol and grapefruit juice; they can affect drug levels and increase side effects.,Practice good oral hygiene with regular brushing and flossing to prevent gum overgrowth.,Report any rash, fever, sore throat, or easy bruising immediately—these may signal serious blood disorders.,Use non-hormonal contraception if on birth control; phenytoin reduces efficacy of oral contraceptives.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Wear a medical alert bracelet if you have epilepsy.,Do not take antacids within 2 hours of phenytoin.,Regular blood tests are needed to monitor drug levels and liver function.,If you become pregnant, discuss with your doctor immediately.
Swallow capsules whole; do not crush or chew.,Take with or without food; avoid high-fat meals which may delay absorption.,May cause dizziness, drowsiness, or blurred vision; avoid driving until effects known.,Drink plenty of fluids to reduce risk of kidney stones.,Stop taking and contact doctor if you experience eye pain, vision changes, or fever.,Use effective contraception during treatment; inform doctor if pregnant or planning pregnancy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIPHENYLAN SODIUM vs ELEPSIA XR, answered by our medical review team.
DIPHENYLAN SODIUM is a Antiepileptic that works by Phenytoin, the active component, stabilizes neuronal membranes by promoting sodium efflux and inhibiting sodium influx, thereby limiting the spread of seizure activity. It also reduces voltage-gated sodium channel activity.. ELEPSIA XR is a Antiepileptic that works by Levetiracetam, the active component, binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. The exact mechanism of antiepileptic effect is unknown.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIPHENYLAN SODIUM and ELEPSIA XR depend on the specific clinical indication. These are both Antiepileptic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIPHENYLAN SODIUM is: 100 mg orally every 8 hours. The standard adult dose of ELEPSIA XR is: ELEPSIA XR (levetiracetam extended-release) 1000 mg orally once daily. May be increased by 1000 mg/day every 2 weeks to a maximum of 3000 mg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIPHENYLAN SODIUM and ELEPSIA XR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIPHENYLAN SODIUM is classified as Category C. First trimester: Increased risk of major congenital malformations including neural tube defects, cleft palate, and congenital heart defects. Second and third trimesters: Risks of b. ELEPSIA XR is classified as Category C. First trimester: Increased risk of major congenital malformations including neural tube defects, cleft palate, and cardiac defects due to folate antagonism. Second and third trimes. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.